Skip to main content
. 2013 May 16;2013:427405. doi: 10.1155/2013/427405

Table 2.

Results of univariate analyses showing relationships among clinicopathological characteristics of specimens.

Variables Lymph node metastasis Remnant of primary tumor
Subject P value Subject P value
Total 4/41 (9.8%)   6/41 (14.6%)  

Sex   0.729   0.386
 Male 4/38 (10.5%)   5/38 (13.2%)  
 Female 0/3   1/3 (33.3%)  
Age (years)   0.488   0.566
 ≤70 3/25 (12.0%)   4/25 (16.0%)  
 >70 1/16 (6.3%)   2/16 (12.5%)  
Endoscopic treatment   0.355   0.015*
 Mucosal resection 0/9   4/9 (44.4%)  
 Submucosal dissection 4/32 (12.5%)   2/32 (6.3%)  
Tumor size (mm)   0.445   0.488
 ≤20 3/24 (12.5%)   3/24 (12.5%)  
 >20 1/17 (5.9%)   3/17 (17.6%)  
Depth of tumor invasion†   0.404   0.077
 pT1a–1b1 0/8   3/8 (37.5%)  
 pT1b2 4/33 (12.1%)   3/33 (9.1%)  
Macrotype   0.156   0.566
 Elevated 3/16 (18.8%)   2/16 (12.5%)  
 Depressed 1/25 (4.0%)   4/25 (16.0%)  
Intratumoral ulceration or ulcer scar   0.582   0.852
 No 4/36 (11.1%)   5/36 (13.9%)  
 Yes 0/5   1/5 (20.0%)  
Main histologic type‡   0.517   0.639
 Differentiated 4/35 (11.4%)   5/35 (14.3%)  
 Undifferentiated 0/6   1/6 (16.7%)  
Undifferentiated component‡   0.578   0.672
 No 3/27 (11.1%)   4/27 (14.8%)  
 Yes 1/14 (7.1%)   2/14 (14.3%)  
Lymphatic invasion   0.284   0.307
 L0 1/21 (4.8%)   2/21 (9.5%)  
 L1 3/20 (15.0%)   4/20 (20.0%)  
Venous invasion   0.030*   0.157
 V0 0/23   5/23 (21.7%)  
 V1 4/18 (22.2%)   1/18 (5.6%)  
Horizontal margin†   0.582   0.001**
 HM0 or HMX 4/37 (10.8%)   3/37 (8.1%)  
 HM1 0/4   3/4 (75.0%)  
Vertical margin†   0.047*   0.228
 VM0 or VMX 2/27 (7.4%)   2/27 (7.4%)  
 VM1 2/14 (14.3%)   4/14 (28.6%)  

*P < 0.05, **P < 0.01.

†According to the third English edition of the Japanese Classification of Gastric Carcinoma.

‡Differentiated: well-differentiated adenocarcinoma, moderately differentiated adenocarcinoma, or papillary adenocarcinoma; undifferentiated: poorly differentiated adenocarcinoma, signet-ring cell adenocarcinoma, or mucinous adenocarcinoma.